Class IA phosphoinositide 3-kinase alpha (PI3Kα) is an important drug target because it is one of the most frequently mutated proteins in human cancers.
Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based Biopharmaceutics Modeling and Bioequivalence Safe Space
The use of physiologically based biopharmaceutics modeling (PBBM) and bioequivalence safe space is increasingly common for immediate-release drug products.
Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs
Physiologically based pharmacokinetics (PBPK) models are increasingly used in the drug research and development, especially in anti-cancer drugs.
Advanced In Vivo Prediction by Introducing Biphasic Dissolution Data into PBPK Models
Coupling biorelevant in vitro dissolution with in silico physiological-based pharmacokinetic (PBPK) tools represents a promising method to describe...
Best Practices for Data Visualisation
Best Practices for Data Visualisation (for the Royal Statistical Society) contains insights, advice, and examples (with code) to make data outputs more impactful.
Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug–Drug Interactions
Index substrates and inhibitors to investigate the role of the polymorphic enzyme, cytochrome P450 (CYP) 2D6, in the metabolism of new compounds have been proposed by regulatory agencies.
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials
There is a major need for effective, well-tolerated treatments for idiopathic pulmonary fibrosis (IPF).
Leveraging the use of in vitro and computational methods to support the development of enabling oral drug products: An InPharma commentary
Due to the strong tendency towards poorly soluble drugs in modern development pipelines, enabling drug formulations such as amorphous solid dispersions...
Simulations Plus Releases ADMET Predictor® 11
New functionality, models, and partner data power predictive accuracy from the industry-leading machine learning platform
Therapeutic Potential and Predictive Pharmaceutical Modeling of Stilbenes in Cannabis sativa
Cannabis sativa is a plant used for recreational and therapeutic purposes; however, many of the secondary metabolites in the plant have not been thoroughly investigated.
July 2023 GastroPlus Newsletter
GastroPlus® Newsletter July 2023
Projection of Target Drug Particle Size in Oral Formulations Using the Refined Developability Classification System (rDCS)
Dissolution limitations to oral absorption can occur if the time required for dissolution is longer than the transit time across the small intestine and/or if dissolution is slower than the drug’s permeation through the gut wall.
Physiologically based pharmacokinetic (PBPK) modelling of oral drug absorption in older adults – an AGePOP review
The older population consisting of persons aged 65 years or older is the fastest-growing population group and also the major consumer of pharmaceutical products.
In silico modeling as a support tool in the development of new products in the generic pharmaceutical industry: case studies of the application of DDDPlus™ and GastroPlus® software
During this webinar, we will shed light on the key benefits and practical implications of utilizing in silico modeling for formulation optimization, biopharmaceutical predictions, and bioequivalence studies
Biopolymer-Capped Pyrazinamide-Loaded Colloidosomes: In Vitro Characterization and Bioavailability Studies
This study aimed to prepare colloidosome particles loaded with pyrazinamide (PZA).
Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results
Total revenue of $16.2 million and diluted earnings per share (EPS) of $0.20
Maintains full-year revenue guidance of $59.3 - $62.0 million (+10-15%) and EPS guidance of $0.63 - $0.67